2014 ACR/ARHP Annual Meeting

November 14-19, 2014. Boston, MA.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 595

Radiographic Sacroiliitis Progression in an Early Axial Spondyloarthritis Cohort
Abstract Number: 2138

Radiological Outcomes after Two Years of Remission Steered Treatment in Early Arthritis Patients
Abstract Number: 2262

Raloxifene for Osteoporosis in Postmenopausal Women with Rheumatic Diseases
Abstract Number: L11

Raman Spectroscopy: Point of Service Diagnosis Is Sensitive and Specific-a Tool for Improving Accuracy and Reducing Future Hospital Admission
Abstract Number: 2860

Randomised Comparison of the Effectiveness of a Non-Pharmacological Multidisciplinary Face-to-Face Group-Based Treatment Program Vs. a Telephone-Delivered Treatment Program on Daily Function in Patients with Generalized Osteoarthritis
Abstract Number: 1843

Randomised Controlled Non-Inferiority Study of Dose Reduction and Withdrawal of Adalimumab and Etanercept in Rheumatoid Arthritis
Abstract Number: 977

Randomized Clinical Trial of a Patient and Provider Intervention for Managing Osteoarthritis in Veterans
Abstract Number: 891

Randomized Clinical Trial of Group Vs. Individual Physical Therapy for Knee Osteoarthritis
Abstract Number: 2859

Randomized Controlled Trial of Postoperative Care Navigation in Total Knee Arthroplasty Patients: Does One Size Fit All?
Abstract Number: 920

Randomized Controlled Trial to Assess the Safety and Efficacy of Odanacatib in the Treatment of Men with Osteoporosis
Abstract Number: L19

Randomized Trial of Stopping TNF-Inhibitors in Rheumatoid Arthritis Patients with Stable Low Disease Activity in the Netherlands
Abstract Number: 238

RANKL and OPG Gene Polymorphisms: Association with Vertebral Fractures and Bone Mineral Density in Premenopausal Systemic Lupus Erythematosus
Abstract Number: 2722

Rapamycin Corrects GATA-3 Deficiency in Lupus Treg
Abstract Number: 1486

Rapid Onset of Clinical Benefit Is Associated with a Reduction in Validated Biomarkers of Disease in Patients with Rheumatoid Arthritis Treated with Mavrilimumab, a Human Monoclonal Antibody Targeting GM-CSFRÃ¡
Abstract Number: 1656

Rate of Histological Transformation to Higher Grade Nephritis in Class II Mesangial Proliferative Lupus Glomerulonephritis

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].